Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
RESEARCH TOOLSreports
Holding PRLD?
Track your performance easily
PRLD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.10 - $6.80
Previous Close$1.29
Volume125.75K
Average Volume (3M)338.54K
Market Cap
$66.03M
Enterprise Value-$95.61M
Total Cash (Recent Filing)$179.84M
Total Debt (Recent Filing)$18.20M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Mar 12, 2025EPS Estimate
-$0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.93
Shares Outstanding55,024,470
10 Day Avg. Volume465,382
30 Day Avg. Volume338,541
Standard Deviation0.28
R-Squared0.07
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)0.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.72
Forecast
1Y Price Target
$4.25Price Target Upside221.97% Upside
Rating ConsensusHold
Number of Analyst Covering4
Prelude Therapeutics News
PremiumCompany Announcements
Prelude Therapeutics Shows Strong Q3 2024 Financial Results
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyImproved efficacy at higher doses of PRT3789 was observed, with notable responses in patients with specific mutations.
Investment OpportunityAnalyst reiterates a Market Outperform rating on Prelude Therapeutics, highlighting the company as a unique investment opportunity, especially after a recent selloff.
Safety ProfileSafety data indicates PRT3789 is generally well tolerated, with no dose-limiting toxicities reported, and suggests potential for higher dosing.
Bears Say
Adverse EventsThere was a noticeable increase in reported Grade 3+ adverse events, rising from 51% to 54%.
Stock Market ComparisonThe stock experienced a steep drop of nearly 43%, contrasting sharply with a 2.2% increase in the XBI benchmark's value.
Stock PerformancePrelude's stock has dramatically declined by approximately 50% following the release of early Phase 1 data for PRT3789 at ESMO.
---
Ownership Overview
60.88% Insiders
6.01% Mutual Funds
<0.01% Other Institutional Investors
29.02% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRLD FAQ
What was Prelude Therapeutics’s price range in the past 12 months?
Prelude Therapeutics lowest stock price was $1.10 and its highest was $6.80 in the past 12 months.
What is Prelude Therapeutics’s market cap?
Currently, no data Available
When is Prelude Therapeutics’s upcoming earnings report date?
Prelude Therapeutics’s upcoming earnings report date is Mar 12, 2025 which is in 125 days.
How were Prelude Therapeutics’s earnings last quarter?
Prelude Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.43 earnings per share for the quarter, beating the consensus estimate of -$0.472 by $0.042.
Is Prelude Therapeutics overvalued?
According to Wall Street analysts Prelude Therapeutics’s price is currently Undervalued.
Does Prelude Therapeutics pay dividends?
Prelude Therapeutics does not currently pay dividends.
What is Prelude Therapeutics’s EPS estimate?
Prelude Therapeutics’s EPS estimate is -$0.49.
How many shares outstanding does Prelude Therapeutics have?
Prelude Therapeutics has 42,174,210 shares outstanding.
What happened to Prelude Therapeutics’s price movement after its last earnings report?
Prelude Therapeutics reported an EPS of -$0.43 in its last earnings report, beating expectations of -$0.472. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Prelude Therapeutics?
Among the largest hedge funds holding Prelude Therapeutics’s share is Baker Bros Advisors LP. It holds Prelude Therapeutics’s shares valued at 39M.
---
Prelude Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.25%
12-Months-Change
Fundamentals
Return on Equity
-58.45%
Trailing 12-Months
Asset Growth
-20.07%
Trailing 12-Months
Company Description
Prelude Therapeutics
Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
---
PRLD Stock 12 Month Forecast
Average Price Target
$4.25
▲(221.97% Upside)
Technical Analysis
Adaptimmune Therapeutics
―
Precision BioSciences
―
Fate Therapeutics
―
Gritstone bio
―
Best Analysts Covering PRLD
1 Year
1 Year Success Rate
4/12 ratings generated profit
1 Year Average Return
-16.22%
reiterated a buy rating 10 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -16.22% per trade.
---